非霍奇金淋巴瘤患者P-gp、P26-bcl-2表达的临床研究  

Clinical study of P-gp, and bcl-2 protein expression in non-Hodgkin's lymphomas patients

作　　者：傅小玉[1] 于丁[1] 毛永荣[1] 杨小玲[1] 何家林[1] 柯玉华[1] 杨玲[1] 蒋晖[1] 吴昌鸣[1] 邓华邦[1] 

机构地区：[1]湖北省肿瘤医院,武汉430079

出　　处：《中华血液学杂志》2001年第6期310-312,共3页Chinese Journal of Hematology

摘　　要：目的　探讨多药耐药基因mdr 1及其蛋白P gp、凋亡抑制基因bcl 2及其相关蛋白P2 6 bcl 2在中、高度恶性非霍奇金淋巴瘤 (NHL)患者中表达的临床意义及潜在的预后价值。方法　应用免疫组织化学S P法对 6 0例NHL患者进行检测。结果　 6 0例患者中P gp表达阳性者 15例 ,P2 6 bcl 2表达阳性者 2 5例。P gp和P2 6 bcl 2共同表达为阴性者的 3年生存率明显高于阳性表达者 (分别为48 48%和 15 .38% ,P =0 .0 38)。结论　P gp、P2 6 bcl 2表达与中、高度恶性NHL患者的化疗效果及预后相关。P gp和P2 6 bcl 2共同表达情况可作为预测中、高度恶性NHL患者化疗敏感性及预后的指标 。Objective To investigate the relationship between the expression of P gp, P26 bcl 2 and the prognosis in intermediate and high grade non Hodgkin's lymphomas(NHL). Methods Sixty cases of intermediate and high grade NHL were retrospectively reviewed using immunohistochemical method. All patients were received CHOP chemotherapy over 4 courses. Results P gp was identified in 15 and P26 bcl 2 in 25 cases. The 3 year survival rates for patients with P26 bcl 2(+) and P26 bcl 2(-) were 37.64% and 76.80%, respectively (P<0.005), and for patients with both positive P gp and P26 bcl 2 and both negative were 15.38% and 48.48%,respectively (P=0.038). Conclusions There is direct relationship between the P gp, P26 bcl 2 protein expression and the prognosis in intermediate and high grade non Hodgkin's lymphoma.

关 键 词：非霍奇金淋巴瘤 多药抗药性 基因表达 P-GP P26-bcl-2 预后 

分 类 号：R733.1[医药卫生—肿瘤]